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1. Abstract 
 
 
Background: There is increasing evidence of aspirin resistance for the prevention of 
cardiovascular events in a substantial proportion of diabetes mellitus. Genetic 
variants influencing aspirin metabolism may contribute to the failure of aspirin therapy 
in patients with diabetes. Aspirin is metabolized by uridine diphosphate 
glucuronosyltransferase isoenzyme 1A6 (UGT1A6). A missense mutation, T181A of 
the UGTA6, has been associated with 30-50% lower enzyme activity as compared to 
the wild-type. 
Methods: In this cross-sectional pilot study, macrovascular complications were 
assessed as a function of the UGT1A6 polymorphism in 74 diabetic patients on 
aspirin therapy. 
Results: Of the 74 diabetic patients treated with 100mg aspirin daily, 48 (65%) 
carried the UGT1A6 polymorphism (37 with allele TA; 11 with TT allele) and 26 (35%) 
the wild-type (AA). The prevalence of macrovascular complications was 35% in 
carriers of UGT1A6 polymorphism as compared to 62% in wild-type carriers 
(p=0.031). In a multiple regression analysis considering possible confounding 
variables, the prevalence of macrovascular complications remained significantly 
associated with the UGT1A6 polymorphism. 
Conclusions: UGT1A6 polymorphism may be associated with decreased 
macrovascular complications in diabetic patients treated with aspirin. 
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2. Introduction 
 
 
In patients with diabetes, prescription of low-dose aspirin for the prevention of 
cardiovascular events is well established (1, 2, 3), although this measure is still 
debated. A recent meta-analysis did not show a significant preventive effect or aspirin 
in diabetic patients (4) and, in primary prevention, low-dose aspirin was less effective 
in diabetic patients compared to patients with other risk factors. 
Aspirin metabolism may contribute to the efficacy of aspirin therapy. The elimination 
rate of aspirin and its metabolic salicylic acid is likely a major factor determining drug 
efficacy among aspirin users. Salicylic acid is glucuronidated by the uridine 
diphosphate glucuronosystransferase isoenzyme 1A6 (UGT1A6) and glucuronidation 
activity may be a critical determinant in aspirin elimination (6). The common 
missense mutation, T181A of the UGT1A6, has been associated with 30-50% lower 
enzyme activity compared with the wild-type (7) in vitro. In a clinical context among 
aspirin users, carriers of the allelic UGT1A6 showed a decreased risk of colorectal 
adenoma in patients with slower glucuronidation of aspirin (8, 9). 
 
In this cross-sectional pilot study, we assessed macrovascular complications as a 
function of the UGT1A6 polymorphism in diabetic patients on aspirin therapy. 
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3. Methods 
 
 
Patients and Methods 
 
Patients with diabetes attending the University Hospital of Zurich as out-patients, 
were invited to participate. Inclusion criteria were diabetes mellitus and treatment with 
aspirin 100mg daily. Exclusion criteria for the study were acute or chronic 
inflammatory disease, cancer, immunosuppression, and treatment with 
glucocorticoids or glitazones. The study population was the same as in a previous 
study (10), with the exception of 2 patients who were excluded because they were 
treated with 300mg aspirin daily. The study protocol was approved by the Ethics 
Committee of the University Hospital of Zurich, and all patients gave written informed 
consent. 
Assessment of clinical parameters and laboratory work were carried out 
independently by different and blinded study physicians. The occurrence of 
macrovascular complications under aspirin therapy were assessed retrospectively 
from medical records. Coronary artery disease was defined as history or either  
myocardial infarction, coronary angioplasty or bypass surgery; cerebrovascular 
disease as history of apoplexy or carotid artery surgery; peripheral artery disease as 
history of angioplasty or bypass surgery of peripheral arteries. Retinopathy, 
neuropathy, and nephropathy were assessed from the medical records as 
established diagnoses. Genomic DNA was isolated from peripheral blood 
mononuclear cells. GHR exon 3 and TNF-α-308 promoter genotyping were carried 
out on a LightCycler (Roche Molecular Biochemicals, Rotkreuz, Switzerland) using 
ToolSets containing specific primers and fluorescent probes (Genes-4U AG, Zurich) 
according to the manufacturer’s instructions. Serum concentrations of  
hs-C-reactive protein was determined on an Immulite 2000 Immunology Analyzer 
using commercial assays from DPC (Los Angeles, CA, USA). TNF- α, Interleukin 1-β 
and interleukin 6 were determined by Luminex technology using commercially 
available multianalyte profiling kits (R&D Systems) and solid-phase enzyme amplified 
sensitivity immunoassay (EASIA), respectively. 
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Statistics 
Statistical analysis was performed using Statistica version 6. Variables were 
compared using either Student’s t-test, Mann-Whitney U-test, or X²-test. Multiple 
regression analysis was performed on the number of patients with macrovascular 
complications. Variables with uncertain influence (p>0.10) were excluded during 
analysis using a stepwise backward elimination procedure. The threshold of 
significance was defined at α=0.05. 
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4. Results 
 
 
Clinical and biochemical characteristics of 74 included patients with diabetes and 
treatment with aspirin 100mg daily are given in Table 1. 48 (65%) of the 74 patients 
carried the UGT1A6 polymorphism (37 heterozygous, allele TA; 11 homozygous, TT 
allele) and 26 (35%) the wild-type (AA). This corresponds to a mutated UGT1A6 
allele frequency of 40%. Carriers of the UGT1A6 wild-type were more often male 
than those carrying the UGT1A6 polymorphism. With regard to other clinical 
characteristics, cardiovascular risk factors and medical therapy (Table 1 and 2), 
carriers of the UGT1A6 polymorphism and wild-type were well balanced. Whereas 
hs-C-reactive protein, TNF-α and interleukin 6 were comparable between both 
groups, interleukin 1-β serum values were lower in patients carrying the UGT1A6 
polymorphism than in wild-type carriers.  
 
Table 3 shows the frequency of macrovascular complications depending on the 
UGT1A6 polymorphism. The prevalence of macrovascular complications before 
aspirin therapy was initiated (data not shown) was comparable between both groups.  
Under aspirin therapy, the incidence of macrovascular complications was 35% in 
carriers of the UGT1A6 polymorphism compared to 62% in carriers of the wild type 
(p=0.031). Accordingly, the number of macrovascular complications per patient was 
significantly lower in carriers of the UGT1A6 polymorphism compared to carriers of 
the wild-type (p=0.039). 
 
We previously described a significant association of TNF-α G308A polymorphism on 
macrovascular complications in this study population (10). Therefore TNF-α G308A 
polymorphism was added into the stepwise multiple regression analysis - in addition 
to the UGT1A6 polymorphism, cardiovascular risk factors, demographic and 
laboratory data - on the number of patients with macrovascular complications (Table 
4). Both polymorphisms remained significantly associated (TNF-α G 308A 
polymorphism, p=0,02; UGT1A6 polymorphism, p=0.04 with the frequency of 
macrovascular complications, whereas there was a trend for TNF-α (p=0.08). Male 
gender and Interleukin 1-β, both significant in the univariate analyses (see Table 1), 
 7
were no more significantly associated with the number of patients with macrovascular 
complications in the multiple regression analysis. 
Figure 1 shows the proportion of patients with macrovascular complications under 
aspirin therapy according the UGT1A6 T181 A and TNF-α G308A polymorphism. 
Only 19% (3 of 16 patients) of patients carrying both mutations had macrovascular 
complications, whereas 67% (16 of 24 patients) of the wild-type carriers (p=0.003) 
experienced macrovascular complications. 41% (14 of 34 patients) of the patients 
with either UGT1A6 T181 or TNF-α G 308A polymorphism experienced 
macrovascular complications, i.e. significantly less patients compared to the wild-type 
carriers (p=0.049) 
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Table 1. Characteristics of 74 patients with diabetes mellitus. 
 
 
UGT1A6 
T181A polymorphism 
 
 
mutation* 
(n=48) 
wild type 
(n=26) 
p-value 
Age, y 65 ± 10 65 ± 9 0.88 
Male gender, no. (%) 28 (58) 22 (84) 0.021 
Body-mass index, kg/m2 28.5 ± 5.4 27.6 ± 4.0 0.42 
Diabetes duration, y 16.5 ± 12.5 15.5 ± 14.0 0.74 
Diabetes type 1, no. (%)  9 (19) 6 (23) 0.66 
Diabetes type 2 with insulin therapy, no. (%) 22 (46) 10 (38) 0.54 
Diabetes type 2 without insulin therapy, no. (%) 17 (35) 10 (38) 0.80 
Hemoglobin A1c,  %  7.5 ± 1.1 7.2 ± 0.8 0.12 
Retinopathy, no. (%) 21 (44) 8 (31) 0.22 
Neuropathy, no. (%) 36 (75) 20 (77) 0.85 
Nephropathy, no. (%) 23 (48) 14 (54) 0.63 
Duration of aspirin therapy, y  4.75 ± 4.6 5.5 ± 5.8 0.56 
Smoking (former or persistent), no. 26 (54) 17 (65) 0.35 
Arterial Hypertension, no. (%) 41 (85) 22 (85) 0.93 
Total cholesterol (mmol/L) 4.96 ± 0.86 4.73 ± 0.78 0.28 
LDL-cholesterol (mmol/L) 2.76 ± 0.79 2.74 ± 0.67 0.93 
HDL-cholesterol (mmol/L) 1.43 ± 0.43 1.32 ± 0.49 0.33 
Triacylglycerols (mmol/L) 1.67 ± 0.94 1.45 ± 0.58 0.30 
hs-C-reactive protein, mg/L 2.7 (0.3-50.1) 1.8 (0.5-56.6) 0.36 
TNF-α, ng/L 6.4 (1.4-12.2) 6.4 (4.0-31) 0.97 
Interleukin 1-, ng/L 1.0 (0.2-2.5) 1.4 (0.02-3.4) 0.010 
Interleukin 6, ng/L 4.9 (1.3-15.3) 4.3 (1.9-10.5) 0.23 
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Values are mean ± SD, numbers of patients (%) or medians with range; p-values were calculated by 
Student’s t-test, χ2 test or Mann Whitney U Test. * 37 heterozygotes (T181/A181), 11 homozygotes 
(A181/A181). 
Table 2. Actual therapy of 74 patients with diabetes under aspirin therapy.  
 
 
 
UGT1A6  
 T181A polymorphism 
 
 
mutation 
(n=48) 
wild type 
(n=26) 
p-value 
β Blocker, no. (%) 28 (58) 13 (50) 0.49 
ACE Inhibitors, no. (%)  27 (56) 16 (62) 0.66 
AT II-Receptor Inhibitors, no. (%) 9 (19) 3 (12) 0.42 
Calcium antagonist, no. (%) 8 (17) 7 (27) 0.29 
Diuretics, no. (%) 19 (40) 10 (38) 0.92 
Statins, no. (%) 31 (65) 20 (77) 0.27 
Nitrates, no. (%) 8 (17) 1 (4) 0.11 
Values are numbers of patients (%); p-values were calculated by χ2 test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 10
 
Table 3. Macrovascular complications of 74 diabetic patients under low dose aspirin  
therapy as a function of polymorphism UGT1A6 T181A polymorphism.   
 
 
UGT1A6 
T181A polymorphism 
 
 mutation 
(n=48) 
wild type 
(n=26) 
p-value 
Macrovascular complications of atherosclerosis under low dose 
aspririn therapy, no. of patients (%) 
   
    - All patients  (n=74)  
     
17 (35) 16 (62) 0.031 
    - Male patients  (n=50) 9 (32) 13 (59) 0.06 
 
    - Female patients  (n=24) 
 
8 (40) 
 
3 (75) 
 
0.20 
 
- Coronary (myocardial infarction, angioplasty or bypass surgery 12 (25) 9 (35)  
- Peripheral arteries (percutanous angioplasty) 8 (17) 7 (27)  
- Cerebrovascular (apoplexy or carotid endarterectomy ) 2 (4) 4 (15)  
Number of complications, no. of patients (%):      0.039 
    0 26 (75) 10 (38)  
    1 12 (25) 9 (35)  
    ≥ 2 5 (10) 7 (27)  
P-values were calculated by χ2 test and Mann-Whitey U Test (Number of complications). 
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Table 4. Stepwise, multiple regression analysis of cardiovascular risk factors, demographic and 
laboratory data on the number of patients with atherosclerotic manifestations under aspirin therapy. 
 
  Number of patients with 
atherosclerotic manifestations 
 β p-value 
Variables remaining in the model   
TNF-α promoter G308A polymorphism -0.29 0.020 
UGT1A6 T181A polymorphism -0.24 0.040 
Log TNF-α,  ng/L   0.20 0.08 
Variables excluded from the model   
Statine treatment 0.17 0.14 
Cholesterol/HDL-Ratio 0.16 0.16 
Body-mass index -0.16 0.19 
Smoking (former and current) 0.12 0.28 
Type of diabetes 0.16 0.29 
Diabetes duration 0.12 0.30 
Log Hemoglobin A1c    -0.12 0.35 
Log Interleukin 6, ng/L   -0.13 0.36 
Log hs-C-reactive protein, mg/L 0.11 0.39 
Log Interleukin 1-, ng/L -0.13 0.41 
Male gender   -0.09 0.44 
Insulin therapy   -0.08 0.54 
Log  Trialcylglycerols -0.05 0.78 
Arterial Hypertension  0.01 0.91 
Age -0.01 0.94 
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Figure Percent of diabetic patients (n=74) with macrovascular complications under 
aspirin therapy according the UGT1A6 T181A and TNF-alpha G-308A 
polymorphisms. Wt/mut stands for patient with either UGT1A6 T181 or TNF-alpha G-
308A polymorphisms. * denotes p<0.05, ** p<0.01. 
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5. Discussion 
 
 
In the present study population of diabetic patients treated with 100mg aspirin, the 
UGT1A6 polymorphism was significantly associated with the frequency of 
macrovascular complications. The incidence of macrovascular complications was 
lower in carriers of the UGT1A6 allele (TA+AA) than in homozygous carriers of wild-
type alleles (TT). 62% of patients with the UGT1A6 wild-type versus 35% with 
mutated UGT1A6 polymorphism experienced macrovasular complications despite 
aspirin therapy. Aspirin and its metabolism salicylic acid are glucuronidated by 
UGT1A6 (6). Lower enzyme activity in carriers of the UGT1A6 polymorphism may 
lead to diminished drug elimination and therefore enhanced drug efficacy among 
aspirin users. UGT1A6 polymorphism has been shown to be associated with 30-50% 
lower enzyme activity compared with the wild-type (7).  
Inhibition of cyclooxygenase-1 (COX-1) and therefore thromboxane (TXA2)-
dependent platelet activation has been claimed to be the major mechanism of aspirin 
(ASA) in the prevention of cardiovascular events. Pronounced (ASA-) drug efficiency 
in patients with UGT1A6 polymorphism is however unlikely to be explained by the 
COX-1 pathway because even small amount of ASA can cause complete COX-1-
blockade with no further benefit with higher ASA dosages (12). Thus, COX-1 
independent ASA effects may be responsible for the decreased incidence of 
macrovascular complications in carriers of the UGT1A6 polymorphism. COX-2 is 
mainly activated by inflammatory processes in monocytes/macrophages or shear 
stress in vascular endothelial cells. Increased (locally) ASA concentrations in patients 
with mutated UGT1A6 would result in less pro-atherogenic TXA2 production and 
enhanced locally anti-inflammatory ASA effects (13). Furthermore enhanced aspirin 
COX-2 triggered generation of lipoxin - a recently found anti-inflammatory mediator - 
may result (14). Other possible aspirin sensitive mechanisms include diminished 
release of pro-inflammatory mediators such as tissue factors (TF) (15), soluble CD40 
ligand (16, 17), reactive oxygen species (ROS) (18) or nuclear factor kB (19). We 
expected lower inflammatory markers in patients carrying the UGTA61 
polymorphisms. However, interleukin 1- β serum levels were found to be lower in 
carriers of the UGT1A6 polymorphism. 
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We previously reported an association of TNF-α promoter G308A polymorphism and 
macrovascular complications in the same study population. Patients with the TNF-α 
promoter G308A polymorphism exhibited lower inflammatory cytokines (such as hs-
C-reactive protein) than wild-type carriers. Using multiple regression analysis, both 
polymorphisms remained significantly associated with the incidence of macrovascular 
complications, i.e. carriers of both mutations had a lower incidence of macrovascular 
complications compared to wild-type carriers (figure).  
 
There are several limitations to our study. First we did not measure aspirin 
metabolites. However, measurement of aspirin or its metabolites is not particularly 
informative because of rapid clearance in the gut and exerting their effects mainly in 
the presystemic circulation (21). In addition, we did not assess platelet function. 
Whether changes in these functional tests accurately reflect platelet activation and 
inhibition in vivo, however, is still unclear (22). Moreover, the correlation between 
results of different tests on aspirin responsiveness is poor (23). Another limitation of 
our study is a gender inbalance, i.e. we had more male patients carrying the mutated 
AGT1A6 alleles than wild-type carriers. Nevertheless, multiple regression analyses 
showed no influence of gender regarding macrovascular complications. The major 
limitation of our study is the small number of patients which warrants confirmation by 
additional studies. Finally, we cannot exclude that our observations reflect 
associations with other additional gene variants rather than the investigated 
polymorphisms. However, heritable factors may be crucial concerning individual 
aspirin responsiveness, as recently shown by others (24). 
 
In conclusion we could show for the first time that UGT1A6 polymorphism may be 
associated with the frequency of macrovascular complications in diabetic patients. 
 15
6. References 
 
 
1. Haffner SM. Coronary heart disease in patients with diabetes. N Engl J Med  
2000; 342:1040-2. 
2. Knopp RH, Retzlaff B, Aikawa K, Kahn SE. Management of patients with diabetic 
hyperlipidemia. Am J Cardiol 2003; 91(7A):24E-28E. 
3. Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic 
events. Diabetes Care 2003; 26:2181-8. 
4. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised 
trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke 
in high risk patients. BMJ 2002; 324:71-86. 
5. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A; PPP 
Collaborative Group. Primary prevention of cardiovascular events with low-dose 
aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention 
Project (PPP) trial. Diabetes Care 2003; 26:3264-72. 
6. Kuehl GE, Bigler J, Potter JD, Lampe JW. Glucuronidation of the aspirin metabolite 
salicylic acid by expressed UDP-glucuronosyltransferases and human liver 
microsomes. Drug Metab Dispos 2006; 34(2):199-202. 
7. Ciotti M, Marrone A, Potter C, Owens IS. Genetic polymorphism in the human 
UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological 
implications. Pharmacogenetics 1997; 7(6):485-95. 
8. Bigler J, Whitton J, Lampe JW, Fosdick L, Bostick RM, Potter JD. CYP2C9 and 
UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. 
Cancer Res 2001; 61(9):3566-9. 
 16
9. Chan AT, Tranah GJ, Giovannucci EL, Hunter DJ, Fuchs CS. Genetic variants in 
the UGT1A6 enzyme, aspirin use, and the risk of colorectal adenoma. J Natl Cancer 
Inst 2005; 97(6):457-60. 
10. Krayenbuehl PA, Wiesli P, Schmid M, Schmid C, Ehses JA, Hersberger M, Vetter 
W, Schulthess G. TNF-alpha -308G>A polymorphism modulates cytokine serum 
concentrations and macrovascular complications in diabetic patients on aspirin. Exp 
Clin Endocrinol Diabetes 2007; 115(5):322-6. 
11. Lampe JW, Bigler J, Horner NK, Potter JD. UDP-glucuronosyltransferase 
(UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: 
relationships to serum bilirubin concentrations. Pharmacogenetics 1999; 9(3):341-9.   
12. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet 
thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest  
1982; 69(6):1366-72. 
13. Kobayashi T, Tahara Y, Matsumoto M, Iguchi M, Sano H, Murayama T, Arai H, 
Oida H, Yurugi-Kobayashi T, Yamashita JK, Katagiri H, Majima M, Yokode M, Kita T, 
Narumiya S.  
Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in 
apoE-deficient mice. J Clin Invest 2004; 114(6):784-94. 
14. Chiang N, Bermudez EA, Ridker PM, Hurwitz S, Serhan CN. Aspirin triggers 
antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human 
trial. Proc Natl Acad Sci U S A 2004; 101(42):15178-83. 
15. Rao AK, Vaidyula VR, Bagga S, Jalagadugula G, Gaughan J, Wilhite DB, 
Comerota AJ.  
Effect of antiplatelet agents clopidogrel, aspirin, and cilostazol on circulating tissue 
factor procoagulant activity in patients with peripheral arterial disease. Thromb 
Haemost 2006; 96(6):738-43. 
 17
16. Nannizzi-Alaimo L, Alves VL, Phillips DR. Inhibitory effects of glycoprotein IIb/IIIa 
antagonists and aspirin on the release of soluble CD40 ligand during platelet 
stimulation. 
Circulation 2003; 107(8):1123-8. 
17. Santilli F, Davi G, Consoli A, Cipollone F, Mezzetti A, Falco A, Taraborelli T, 
Devangelio E, Ciabattoni G, Basili S, Patrono C. Thromboxane-dependent CD40 
ligand release in type 2 diabetes mellitus. J Am Coll Cardiol 2006;47(2):391-7. 
18. Nascimento-Silva V, Arruda MA, Barja-Fidalgo C, Fierro IM. Aspirin-triggered 
lipoxin A4 blocks reactive oxygen species generation in endothelial cells: a novel 
antioxidative mechanism. Thromb Haemost 2007; 97(1):88-98. 
19. Weber C, Erl W, Pietsch A, Weber PC. Aspirin inhibits nuclear factor-kappa B 
mobilization and monocyte adhesion in stimulated human endothelial cells. 
Circulation 1995; 91(7):1914-7. 
20. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A; PPP 
Collaborative Group. Primary prevention of cardiovascular events with low-dose 
aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention 
Project (PPP) trial. Diabetes Care 2003; 26:3264-72. 
21. Maree AO, Fitzgerald DJ.Variable platelet response to aspirin and clopidogrel in 
atherothrombotic disease. Circulation 2007; 115(16):2196-207. 
22. Patrono C, Rocca B. Drug insight: aspirin resistance--fact or fashion? Nat Clin 
Pract Cardiovasc Med 2007; 4(1):42-50.  
23. Harrison P, Segal H, Blasbery K, Furtado C, Silver L, Rothwell PM. Screening for 
aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 
point-of-care platelet function tests with optical aggregometry.  
Stroke 2005; 36(5):1001-5. 
 18
24. Faraday N, Yanek LR, Mathias R, Herrera-Galeano JE, Vaidya D, Moy TF, Fallin 
MD, Wilson AF, Bray PF, Becker LC, Becker DM. Heritability of platelet 
responsiveness to aspirin in activation pathways directly and indirectly related to 
cyclooxygenase-1. Circulation 2007; 115(19):2490-6. 
 
 19
7. Verdankungen 
 
 
Ich möchte allen, die mir die Arbeit an der Dissertation erleichterten und 
ermöglichten, ganz herzlich Danken.  
 
 Peter Wiesli, für seine Betreuung und seine Geduld. 
 Dem Endokrinologie-Team des Universitätsspitals Zürich, besonders Pierre-
Alexandre Krayenbühl für seine tatkräftige Unterstützung. 
 Meiner Familie für die moralische Unterstützung. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 20
 21
8. Curriculum vitae 
 
 
Persönliche Daten 
Name   Marianne SCHMID 
Geburtsdatum 27.02.1977 
Geburtsort  Bülach (ZH) 
Bürgerort  Glattfelden (ZH) 
Zivilstand  ledig 
 
Ausbildung 
1984-1990              Primarschule Glattfelden 
1990-1992 Sekundarschule Glattfelden 
1992-1997 Gymnasium KZU Bülach 
1997   Eidgenössische Matura Typus B 
1997-2004  Studium der Humanmedizin an der Universität Zürich 
2004   Eidgenössisches Staatsexamen 
  
Weiterbildung 
 
05/05-09/06  Assistenzärztin Chirurgie 
   Spital Zimmerberg, Horgen 
Seit 1.11.2006 Assistenzärztin Anästhesiologie 
   Kantonsspital Aarau 
 
